Latest Hotspot

Monte Rosa Therapeutics reveals preclinical results, suggesting that MRT-6160, could treat immune-based and inflammatory disorders

16 November 2023
3 min read

Monte Rosa Therapeutics, Inc., a firm in the clinical-stage biotechnology sector that produces medicines based on novel molecular glue degrader (MGD), has disclosed that it will share initial experimental results at the American College of Rheumatology Convergence Annual Meeting taking place in San Diego, CA, between November 10-15. The findings reveal that MRT-6160, an innovative, highly selective MGD that targets VAV1, had a mitigating effect on disease advancement in a mouse model of collagen-induced arthritis.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

During lab tests, MRT-6160 demonstrated the ability to selectively degrade VAV1 and suppress the activation and functioning of primary human T-cells and B-cells prompted by TCR and BCR. In the collagen-induced arthritis (CIA) model, the oral administration of MRT-6160 resulted in swift VAV1 breakdown in numerous tissues, in accordance with the dosage. 

Throughout a 20-day period, MRT-6160 noticeably reduced the progress of the disease and final functional grades compared to a control vehicle. Also, it pointed towards outstanding performance compared to an anti-TNF antibody.

We're greatly inspired by these findings from our early-stage trials as we think they underscore the significance of VAV1 as a possible therapeutic target for T- and B-cell mediated autoimmune disorders. 

They also point to MRT-6160's potential for wide-spread treatment of diseases caused by autoimmune and inflammation including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and other autoimmune diseases," expressed Dr. Owen Wallace, the Chief Science Officer at Monte Rosa Therapeutics.

Dr. Wallace added, “Combined with comprehensive data from other autoimmune model trials, these encouraging outcomes solidify the position of MRT-6160 as it moves towards clinical stages. We are eager for our expected IND submission in the first half of the forthcoming year.”

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of November 14, 2023, there are 2 investigational drugs for the VAV1 target, including 3 indications, 2 R&D institutions involved,and as many as 1468 patents.

MRT-6160 is a potent, highly selective, and orally bioavailable degrader of VAV1, which has shown deep degradation of its target with no detectable effects on other proteins. Preclinical studies demonstrate MRT-6160 inhibits disease progression in in vivo autoimmunity models.

图形用户界面, 文本, 应用程序

描述已自动生成

What are calcineurin inhibitors and how do you quickly get the latest development progress?
What are calcineurin inhibitors and how do you quickly get the latest development progress?
16 November 2023
Calcineurin inhibitors, acting as immunosuppressive agents, are employed in the treatment of autoimmune disorders like lupus nephritis, atopic dermatitis, interstitial lung disease, and idiopathic inflammatory myositis, among others.
Read →
Sunvozertinib: brief review of its R&D progress and the clinical outcome in 2023 ESMO
ESMO 2023
4 min read
Sunvozertinib: brief review of its R&D progress and the clinical outcome in 2023 ESMO
15 November 2023
Sunvozertinib (DZD9008) is a targeted, irreversible EGFR inhibitor selective for EGFR mutations. Initial findings for sunvozertinib in treating naïve EGFR exon20ins NSCLC were presented at the ESMO Congress.
Read →
At SITC 2023, ENB Therapeutics presented early results from phase one of its ENBOLDEN-101 trial for platinum-resistant ovarian cancer
Latest Hotspot
3 min read
At SITC 2023, ENB Therapeutics presented early results from phase one of its ENBOLDEN-101 trial for platinum-resistant ovarian cancer
15 November 2023
At SITC 2023, ENB Therapeutics showcased preliminary findings from the first phase of its ENBOLDEN-101 trial for platinum-resistant ovarian cancer.
Read →
What are C5 inhibitors and how do you quickly get the latest development progress?
What are C5 inhibitors and how do you quickly get the latest development progress?
15 November 2023
C5 inhibitors can defend against biological attacks and control diseases caused by immune responses.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.